Interleukin 1 Receptor Antagonist Protein

This is a protein that helps control inflammation in the body. It works by blocking a signal that triggers inflammation. It's used as a medication to treat certain types of arthritis, like rheumatoid arthritis. It's usually given by injection.

Brand names:Kineret
Medication

What people taking Interleukin 1 Receptor Antagonist Protein report

Every report comes from a Lived member, sent anonymously.

Have you tried Interleukin 1 Receptor Antagonist Protein for Cryopyrin-Associated Periodic Syndromes?

NameHow it went

About Interleukin 1 Receptor Antagonist Protein

What It's For

Interleukin-1 receptor antagonist protein (IL-1Ra) is a natural protein the body uses to switch off inflammation. As a medicine, it is available as anakinra, sold under the brand name Kineret, a laboratory-made copy of this protein given as a daily injection. Kineret is approved in the US for three uses. In adults with moderately to severely active rheumatoid arthritis that has not responded well enough to at least one standard disease-modifying antirheumatic drug (DMARD, such as methotrexate), it reduces joint pain and swelling and slows joint damage. It is also approved for neonatal-onset multisystem inflammatory disease (NOMID), the most severe form of cryopyrin-associated periodic syndromes (CAPS), and for deficiency of interleukin-1 receptor antagonist (DIRA). Both are rare inherited conditions that cause fever, rash and inflammation from early life, and both can affect children as well as adults. Doctors also prescribe anakinra off-label for other inflammatory conditions driven by interleukin-1, such as adult-onset Still disease and recurrent pericarditis (repeated inflammation of the sac around the heart). Studies in these conditions report good response rates, but they are mostly small, so how much benefit to expect is less certain than for the approved uses.

How It Works

Interleukin-1 is a chemical messenger the immune system releases when it senses injury or infection. It triggers fever, pain and swelling, and in joints it helps break down cartilage and bone. Normally the body balances it with its own receptor antagonist, a protein that sits on the same receptor without switching it on. Anakinra works the same way. It occupies the interleukin-1 receptor so the inflammatory signal cannot get through. In rheumatoid arthritis, the body's own supply of this blocking protein in the joints is not enough to keep up with the interleukin-1 being produced, and anakinra adds more. In CAPS, a faulty gene drives the overproduction of interleukin-1, and in DIRA the body cannot make the blocking protein at all, so anakinra directly replaces what is missing. Because the drug clears from the body within hours, it has to be injected every day to keep working.

Dosage & Administration

Kineret comes as a prefilled syringe containing 100 mg, injected under the skin (subcutaneously) once a day, ideally at about the same time each day. Adults with rheumatoid arthritis use the full 100 mg syringe daily; higher doses did not work better in studies. For NOMID and DIRA, the dose is based on body weight and adjusted by the specialist to control inflammation, so a person may use only part of a syringe. Each syringe is used once and any leftover medicine is thrown away. A nurse or doctor teaches the patient or a caregiver how to inject before they do it at home. Rotating the injection site lowers the chance of skin reactions and of protein deposits building up under the skin. People with severe kidney disease may be told to inject every other day instead, because the kidneys clear the drug. Syringes are kept in the refrigerator and should not be frozen or shaken.

Side Effects

The most common side effect is a reaction where the shot was given: redness, bruising, swelling or pain. In rheumatoid arthritis studies, most people had one, usually in the first month, and they were mostly mild and faded over two to four weeks. Headache, nausea, diarrhea, joint aches, flu-like symptoms and colds or sinus infections are also common. Because anakinra dampens part of the immune response, serious infections such as pneumonia or skin infections are somewhat more common than without it. Fever, chills, a worsening cough or skin that becomes hot, red and painful should be reported to the care team right away. The drug can also lower neutrophils, the white blood cells that fight bacteria, which is why blood counts are monitored. Liver inflammation has also been reported rarely. Severe allergic reactions are uncommon but possible, and people with DIRA are at higher risk during the first several weeks of treatment. Swelling of the face, lips, tongue or throat, or trouble breathing after an injection, needs emergency care by calling 911.

Interactions & Warnings

Anakinra should not be started during an active infection, and the care team usually checks for latent tuberculosis (TB), a hidden infection that immune-suppressing medicines can reawaken, before treatment begins. People with frequent infections, asthma or a weakened immune system need extra care, as serious infections were more common in some of these groups. It is not recommended alongside TNF (tumor necrosis factor) blockers, another family of biologic arthritis drugs that includes etanercept. When anakinra was combined with etanercept in a study, serious infections became more frequent without any added improvement. Live vaccines (vaccines made from weakened living germs) should not be given during treatment, so it helps to review vaccinations before starting. Anakinra is made using E. coli bacteria, so anyone with a known allergy to E. coli-derived proteins should not use it. Information on use during pregnancy and breastfeeding is limited and has not shown a clear risk, while uncontrolled rheumatoid arthritis or CAPS can itself affect pregnancy, so the decision is made with the specialist. The long-term effect on cancer risk is not known.

What to Expect

In CAPS and DIRA, the specialist adjusts the dose step by step until signs of inflammation such as fever and rash are under control. In rheumatoid arthritis, improvement in joint pain and stiffness builds more gradually, and the rheumatologist judges the response over several months. Regular blood tests are part of treatment. Neutrophil counts are checked before starting, monthly for the first three months, and then every three months for up to a year. Daily injections are a real commitment, and in studies skin reactions were the most common reason people stopped, although they usually appear in the first month and fade over a few weeks. For NOMID and DIRA, anakinra is usually a long-term treatment because the underlying cause is genetic, and stopping can bring inflammation back. If a serious infection develops, the care team weighs the risk of a flare against the risk of continuing, so treatment should not be stopped or restarted without their guidance.

Questions to Ask Your Doctor

  1. 1.Why is anakinra a better fit for me than other options, such as a longer-acting interleukin-1 blocker or another biologic?
  2. 2.How will we judge whether it is working, and how long should we give it before deciding?
  3. 3.Which tests do I need before starting, and how often will my blood counts be checked?
  4. 4.What should I do if I get a fever or infection, or need surgery or a vaccine while on treatment?
  5. 5.How do my kidney function, pregnancy plans or other medicines affect how I should take it?

Last reviewed • Oct 2026

Educational content, not medical advice.